Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium(R) 24HR

Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium(R) 24HR

NEW YORK--(BUSINESS WIRE)--March 28, 2014-- 

Today the U.S. Food and Drug Administration (FDA) approved over-the-counter Nexium(R) 24HR (esomeprazole 20mg) marking a key step towards providing those who suffer from frequent heartburn broader access to a brand doctors and patients have trusted for years.
In 2012, Pfizer acquired exclusive global rights from AstraZeneca to market non-prescription Nexium(R) . The addition of Nexium(R) 24HR to the Pfizer Consumer Healthcare portfolio expands the breadth of categories in which we help consumers better manage their health, and extends the value of the world's leading prescription acid blocker brand.
"Switching medicines, whenever appropriate, from prescription to non-prescription status improves access, empowers consumers to care for their own health and is an important strategy for Pfizer," said Paul Sturman, President, Pfizer Consumer Healthcare. "The FDA approval of Nexium(R) 24HR is a significant milestone in executing against our plan."
We continue to work closely with AstraZeneca and retail partners to make Nexium(R) 24HR available to consumers in the U.S., with other markets in Europe expected to follow this year.
Pfizer Inc: Working together for a healthier world(TM)
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at
    CONTACT: Pfizer 
Sally Beatty, 212-733-6566
Ryan Crowe, 212-733-8160
    SOURCE: Pfizer 
Copyright Business Wire 2014 
Access Investor Kit for Pfizer Inc.

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.